Brought to you by 
Intellia Therapeutics raises $70mm in Series B round
03 Sep 2015
Executive Summary
Intellia Therapeutics Inc. (gene editing utilizing CRISPR/Cas9 technology) raised $70mm in its Series B round led by OrbiMed HealthCare Fund Management, which takes a board seat. Fidelity Management & Research Co., Janus Capital Management, Foresite Capital, Sectoral Asset Management, EcoR1 Capital, and other investors participated, along with returning buyers Atlas Venture and partner Novartis AG. Leerink Partners was the placement agent.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Macromolecule
-
Drug Delivery
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
-
Drug Discovery Tools
- Genomics-Proteomics
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Intellia Therapeutics raises $70mm in Series B round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice